Subscribe

Molecure S.A. (MOC.WA)

PLN5.85 -0.06 (-1.02%)
PL WSE Healthcare Biotechnology
Address Zwirki i Wigury 101 02-089
Warsaw, PL
CEO Marcin Jan Szumowski
Website molecure.com
IPO 2018-04-01
ISIN PLONCTH00011

Explore sections of this company profile

Description

Operating as a biopharmaceutical firm in Poland, Molecure S.A. specializes in the research, development, and commercialization of innovative therapies designed to combat neoplastic (cancer) and inflammatory conditions. The company's pipeline prominently features OATD-01, a chitotriosidase/acidic mammalian chitinase inhibitor that has successfully advanced through Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis and sarcoidosis. Additionally, Molecure is progressing its YKL-40 program for cancer and fibrosis, OATD-02 for oncology applications, and a Deubiquitinase program. Established in 2012, this Warsaw-headquartered enterprise adopted the name Molecure S.A. in March 2022, having previously been known as OncoArendi Therapeutics S.A.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
PLN5.85 -0.06 (-1.02%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
45.3K
Beta
1.03
Float Shares
14.41M
Free Float %
69.9%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-0.18% +6.04% -0.35% -27.30% -20.06% -14.33% -7.26% -71.76% -87.98% -80.62% -80.62%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
5.85
DCF (Unlevered) 0.52 -91.0%
DCF (Levered) 0.54 -90.8%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 2 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
7.78
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Biotechnology: +1.6%
    -100.0%
  • ✗
    EPS growth Biotechnology: +29.7%
    +50.3% ★ Q1'26: +23.1% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Biotechnology: +16.2%
    — Q1'26: -16,743.3% (vs Q1'25)
  • ✗
    EBIT margin Biotechnology: +0.0%
    — Q1'26: -34,880.5% (vs Q1'25)
  • ✗
    ROIC Biotechnology: -16.1%
    -28.9% Q1'26: -17.0% (vs Q1'25)
  • ✗
    Share dilution Biotechnology: -3.4%
    +1.3% ★ Q1'26: +2.0% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    -0.28× Q1'26: -0.32× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (1.06) × ERP
WACC = 96% × Ke + 4% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 0.52 Current price: 5.85
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana.
Revenue
3.0K
est: 1.60M (-99.8%)
2.8K
est: 2.00M (-99.9%)
122.94M
est: 2.40M (+5,022.4%)
400.00
est: 900.0K (-100.0%)
7.51M
est: 2.10M (+257.8%)
100.00
est: 1.90M (-100.0%)
2.92M
est: 2.50M (+16.8%)
—
est: 3.33M (-100.0%)
44.03M
44.03M – 44.03M
+1,221.0% YoY
63.50M
63.50M – 63.50M
+44.2% YoY
9.00M
9.00M – 9.00M
-85.8% YoY
EBITDA
-4.38M
est: -1.09M (-303.0%)
-3.85M
est: -1.36M (-183.1%)
73.88M
est: -1.63M (+4,628.1%)
-13.33M
est: -611.8K (-2,078.7%)
-31.85M
est: -1.43M (-2,131.0%)
-25.51M
est: -1.14M (-2,134.1%)
-27.37M
est: -1.50M (-1,724.9%)
-19.03M
est: -2.00M (-851.3%)
-26.42M
-26.42M – -26.42M
-1,221.0% YoY
-38.10M
-38.10M – -38.10M
-44.2% YoY
-5.40M
-5.40M – -5.40M
+85.8% YoY
EBIT
-4.42M
est: -1.09M (-305.9%)
-4.08M
est: -1.36M (-200.3%)
73.70M
est: -1.63M (+4,615.1%)
-13.63M
est: -612.1K (-2,126.6%)
-35.83M
est: -1.43M (-2,408.7%)
-28.37M
est: -1.14M (-2,385.3%)
-31.19M
est: -1.50M (-1,979.6%)
-22.04M
est: -2.00M (-1,001.8%)
-26.42M
-26.42M – -26.42M
-1,221.0% YoY
-38.10M
-38.10M – -38.10M
-44.2% YoY
-5.40M
-5.40M – -5.40M
+85.8% YoY
Net Income
-3.78M
-4.16M
est: -6.06M (+31.4%)
67.96M
est: -6.06M (+1,221.3%)
-13.64M
est: -18.18M (+25.0%)
-13.54M
est: -28.28M (+52.1%)
-28.37M
-31.29M
est: -32.73M (+4.4%)
-15.69M
est: -24.55M (+36.1%)
49.10M
49.10M – 49.10M
+300.0% YoY
53.19M
53.19M – 53.19M
+8.3% YoY
-30.69M
-30.69M – -30.69M
-157.7% YoY
SGA
1.41M
est: 17.20B (-100.0%)
1.58M
est: 21.50B (-100.0%)
2.44M
est: 25.80B (-100.0%)
2.65M
est: 9.67B (-100.0%)
4.60M
est: 22.57B (-100.0%)
4.71M
est: 20.45B (-100.0%)
27.06M
est: 26.87B (-99.9%)
18.05M
est: 35.83B (-99.9%)
473.30B
473.30B – 473.30B
+1,221.0% YoY
682.55B
682.55B – 682.55B
+44.2% YoY
96.74B
96.74B – 96.74B
-85.8% YoY
EPS
-0.28
-0.31
est: -0.30 (-3.3%)
5.00
est: -0.30 (+1,766.7%)
-0.98
est: -0.90 (-8.9%)
-2.56
est: -1.40 (-82.9%)
-1.69
-1.55
est: -1.60 (+3.1%)
-0.77
est: -1.20 (+35.8%)
2.40
2.40 – 2.40
+300.0% YoY
2.60
2.60 – 2.60
+8.3% YoY
-1.50
-1.50 – -1.50
-157.7% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-05-28 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-05-27 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-05-26 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-05-25 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-05-22 C+ 2/5 3/5 1/5 1/5 3/5 1/5 3/5
2026-05-21 C+ 2/5 3/5 1/5 1/5 3/5 1/5 3/5
2026-05-20 C+ 2/5 3/5 1/5 1/5 3/5 1/5 3/5
2026-05-19 C+ 2/5 3/5 1/5 1/5 3/5 1/5 3/5
2026-05-18 C+ 2/5 3/5 1/5 1/5 3/5 1/5 3/5
2026-05-15 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-05-14 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-05-13 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-05-12 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-05-11 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-05-08 C+ 2/5 2/5 1/5 1/5 3/5 1/5 4/5
2026-05-07 C+ 2/5 2/5 1/5 1/5 3/5 1/5 4/5
2026-05-06 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-05-05 C+ 2/5 2/5 1/5 1/5 3/5 1/5 4/5
2026-05-04 C+ 2/5 2/5 1/5 1/5 3/5 1/5 4/5
2026-04-30 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-04-29 C+ 2/5 3/5 1/5 1/5 2/5 1/5 4/5
2026-04-28 C+ 2/5 3/5 1/5 1/5 2/5 1/5 4/5
2026-04-27 C+ 2/5 3/5 1/5 1/5 2/5 1/5 4/5
2026-04-24 C+ 2/5 3/5 1/5 1/5 2/5 1/5 4/5
2026-04-23 C+ 2/5 3/5 1/5 1/5 2/5 1/5 4/5
2026-04-22 C+ 2/5 3/5 1/5 1/5 2/5 1/5 4/5
2026-04-21 C+ 2/5 3/5 1/5 1/5 2/5 1/5 4/5
2026-04-20 C+ 2/5 3/5 1/5 1/5 2/5 1/5 4/5
2026-04-17 C+ 2/5 3/5 1/5 1/5 2/5 1/5 4/5
2026-04-16 C+ 2/5 3/5 1/5 1/5 2/5 1/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-49.88M
OE per share TTM
-2.38
Owner's Yield
-43.08%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
46.5%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
Shares Outstanding
20.60M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Adam Golebiowski Co-Founder & Vice President of Research Chemistry — male
Agnieszka Rajczuk-Szczepanska HR Director — female
Jacek Olczak Co-Founder & Head of Medicinal Chemistry — male
Magdalena Tyszkiewicz Head of CMC — female
Marcin Jan Szumowski Co-Founder, Chief Executive Officer & President of Management Board — male
Monika Czarnecka Finance Director — female
Piotr Iwanowski Chief Medical Officer & Member of Management Board — —
Zbigniew Zaslona Chief Scientific Officer & Member of Management Board — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology